37 results about "Neuroblastic Tumor" patented technology

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and / or secretion and / or abdominal disorders or diseases and / or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

The present invention provides fusion proteins for the detection and treatment of neuroectodermal tumors. Previous work demonstrated that chlorotoxin is specific for glial-derived or meningioma-derived tumor cells. The current invention has extended the use of chlorotoxin-cytotoxin fusion proteins to treat the whole class neuroectodermal tumors such as gliomas, meningiomas, ependymonas, medulloblastomas, neuroblastomas, gangliomas, pheochromocytomas, melanomas, PPNET's, small cell carcinoma of the lung, Ewing's sarcoma, and metastatic tumors in the brain. Also, diagnostic methods are provided for screening neoplastic neuroectodermal tumors.

The invention provides ligands of ganglioside GD2, including peptide ligands such as GGITNYNSALM; YCGGITNYNSACY; YCITNYNSCY; YCGGITNYNCY; YCTNYGVHCY; YCTNYGVCY; GGIANYNTS; YCGGIANYNCY; YCGGIANYNTSCY; and, YCIANYNTCY. GD2 ligands of the invention may for example be used to treat or diagnose diseases such as cancers in which cells express GD2, including neuroblastomas.

The present invention relates to an application of a target nucleic acid detection method using a clamping probe and a detection probe. The method of the present invention can effectively detect a small amount of variation or a specific gene sequence contained in a sample by selective amplification and detection of a trace amount of a target gene to be detected while inhibiting amplification of wild-type genes or undesired genes. Also, it is possible to determine a large number of genotypes at the same time through a melting curve analysis. In particular, the method can be used for diagnosis, prognosis and monitoring of the medical condition of a disease, treatment efficacy evaluation, and for aiding nucleic acid and protein delivery studies and so on, through a very small amount of a mutant genotype that is confirmed at a high detection sensitivity. The method of the present invention comprises a step for evaluating the detection of biomarkers such as EGFR, KRAS, NRAS etc. and the presence of mutations of biomarkers using invasive specimens such as tissues as well as non-invasive specimens (blood, urine, sputum, stool, saliva, and cells). The presence of the biomarker and mutations provides a method used for monitoring of the entire cycle of a related disease, disease prognosis and prediction, decision of disease treatment strategy, disease diagnosis / early diagnosis, disease prevention, and development of disease therapeutics.

The invention relates to naturally or artificially synthesized iso-thiocyanates i.e. JC-5411 compounds and their use in treating and preventing malignant tumor, wherein the compounds can directly suppress the methylation of the gene promoter / 5-UTR area CpG DNA, directly inhibit the reactivity of histone deacethylases (HADC), selectively promote histone acetylation and methylation, then further recover the expression of genes with important functions that are shut abnormally in cancer cells, thus control the malignant proliferation of cancer cells.

A biamidoheterocyclic derivative with antineoplastic activity and its preparing process are disclosed. It can be used to treat cancers, such as chronic granulocyte leukemia, acute lymphocyte leukemia and melanotic cancer etc.

The invention provides a diaryl ethyl diether compound and a pharmaceutically acceptable hydrate or salt as well as a synthetic method and anti-tumor application thereof. A structural general formulais as shown in the description. A preparation method comprises the following steps: dissolving 3-hydroxy-2 nitropyridine into DMF, adding 1,2-dibromoethane and potassium carbonate, and carrying out reaction, so that a compound e is obtained; dissolving the compound e into a solvent DMF, then adding a substance (as shown in the description) and potassium carbonate, then heating, and carrying out reaction, so that a compound d is obtained; reducing the compound d by virtue of iron powder, so that a compound c is obtained; dissolving the compound c into acetonitrile solution, and carrying out bromination reaction, so that a product b is obtained; adding the compound b and 1-(1-t-butyloxycarboryl piperidine-4-yl) pyrazole-4-boronic acid pinacol ester into DME, then adding Pd(dppf)Cl2 and Cs2CO3 aqueous solution, and carrying out reaction, so that a compound a is obtained; and adding the compound a into dichloromethane, dropwise adding 1,4-dioxane solution of hydrogen chloride under ice-bath condition, and carrying out reaction, so that the product is obtained. The compound provided by the invention is novel in structure, has the effect of resisting to non-small cell lung cancer and neuroblastoma and has the antitumor activity equivalent to or better than that of a positive control crizotinib.

The invention belongs to the technical field of biomedicine, and relates to a novel target used for preventing enterovirus 71 infection, and applications thereof. According to the invention, SH-SY5Y is taken as the target cell, and RNA interference technology is adopted for down-regulation of expression of target cell host protein so as to search host factors capable of inhibiting EV71 infection of SH-SY5Y cells effectively and protect the functions of central nervous systems. It is fond by experiments that calcium-and inte-grin-binding protein, CIB1 molecular possesses significant importance in EV71 infection of SH-SY5Y, and down-regulation of expression of CIB1 is capable of inhibiting EV71 infection obviously. The invention also provides applications of CIB1 in preparing drugs used for preventing or treating EV71 infection.